Co-founder & CEO of Rea Diagnostics SA
Rea Diagnostics
Rea Diagnostics develops a smart sanitary pad that detects preterm birth biomarkers in vaginal discharge. The pad transmits risk alerts to physicians, enabling early clinical intervention. This technology aims to reduce unexpected preterm deliveries and improve neonatal outcomes.
- Digital Health
- Hardware
- Healthcare Technology
Updated 23 months ago
Funding
Raised to date
$590KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Preterm birth is a leading cause of infant mortality, and its diagnosis is often complicated and unexpected. Current methods for assessing preterm birth risk can be unreliable, leading to delayed interventions and poorer outcomes for both mother and child.
Solution
Rea has developed a Smart Sanitary Pad that analyzes biomarkers present in vaginal discharge to provide an early assessment of preterm birth risk. The pad identifies key indicators in the discharge, alerting healthcare providers to potential risks. This early warning system enables timely medical interventions, potentially improving outcomes for at-risk pregnancies and reducing the incidence of preterm birth complications. The technology offers a convenient and non-invasive method for monitoring pregnant women, providing valuable insights for proactive care.
Target Audience
The primary target audience includes pregnant women at risk of preterm labor and their healthcare providers, including obstetricians and hospitals.
Features
- Smart Sanitary Pad equipped with biosensors to detect relevant biomarkers in vaginal discharge.
- Real-time analysis of biomarker data to assess preterm birth risk.
- Secure data transmission to healthcare providers for timely intervention.
- Non-invasive and easy-to-use design for convenient at-home monitoring.